Anika Therapeutics, Inc. — Fiscal 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual Form 10-K, not a standalone fourth-quarter filing, although it includes fourth-quarter and full-year disclosures. Anika is a global joint-preservation company focused on osteoarthritis pain management, regenerative solutions, sports medicine, bone-preserving joint solutions and legacy non-orthopedic products.
Business Context
- Revenue is generated through commercial partners, hospitals and ambulatory surgical centers, and distributors.
- Monovisc and Orthovisc remain core products; DePuy Mitek marketed these products exclusively in the United States. The Orthovisc agreement was extended in August 2022 through December 2028, while the Monovisc agreement runs through December 2026.
- The 2020 Parcus Medical and Arthrosurface acquisitions expanded Anika into sports medicine and bone-preserving joint solutions and increased its direct U.S. commercial infrastructure.
- As of December 31, 2022, Anika had 345 full-time employees in the United States and Europe.
Key Financial Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $156.2 million | $147.8 million | Up 6% |
| Gross profit | $93.6 million | $82.9 million | Up 13% |
| Gross margin | 60% | 56% | Up 4 percentage points |
| Operating income (loss) | $(19.4) million | $2.6 million | Declined $22.0 million |
| Net income (loss) | $(14.9) million | $4.1 million | Declined $19.0 million |
| Diluted EPS | $(1.02) | $0.28 | Declined $1.30 |
| Adjusted EBITDA | $12.6 million | $16.4 million | Down $3.8 million |
| Operating cash flow | $4.4 million | $8.4 million | Down $4.0 million |
| Capital expenditures | $7.5 million | $5.1 million | Up $2.4 million |
| Cash and cash equivalents | $86.3 million | $94.4 million | Down $8.1 million |
Adjusted gross profit was $103.0 million and adjusted gross margin was 66% in both 2022 and 2021. Adjusted net loss was $7.1 million in 2022 versus $0.4 million in 2021. These non-GAAP measures exclude selected acquisition-related amortization, product rationalization charges, inventory step-up effects and other items.
Revenue by Product Family
| Product family | 2022 revenue | Year-over-year change |
|---|---|---|
| OA Pain Management | $97.9 million | Up 9% |
| Joint Preservation and Restoration | $50.4 million | Up 4% |
| Non-Orthopedic | $7.9 million | Down 18% |
Growth reflected recovery from COVID-19-related disruptions, higher international sales, favorable partner ordering patterns and increased adoption of newer products. Non-Orthopedic revenue declined primarily because of distributor timing and 2021 last-time purchases of legacy products.
Liquidity, Debt and Balance Sheet
- Cash, cash equivalents and investments totaled $86.3 million at year-end; the filing states that no investments were held at December 31, 2022, so this amount was principally cash and cash equivalents.
- Working capital was $141.6 million, compared with $138.7 million in 2021.
- Anika had no outstanding borrowings under its $75 million senior revolving credit facility and was in compliance with its covenants. Subject to conditions and lender approval, total commitments could be increased to $150 million.
- Total assets were $349.1 million and stockholders’ equity was $285.6 million.
- Operating lease obligations totaled $39.9 million in undiscounted future payments, including $25.2 million due after five years.
Material Changes Versus 2021
- Revenue increased 6%, while gross margin expanded from 56% to 60%, helped by revenue growth and the conclusion of acquisition-related inventory step-up amortization.
- Operating expenses increased 41% to $113.0 million. SG&A increased 14% to $84.8 million due to commercial expansion, marketing, medical education, commissions, travel, stock compensation and corporate costs. Research and development increased 3% to $28.2 million.
- 2021 included a $21.1 million benefit from reducing the fair value of contingent consideration; no comparable benefit was recorded in 2022. Anika paid the remaining $4.3 million Parcus Medical milestone in September 2022, and no acquisition milestones remained at year-end.
- Stock-based compensation increased to $14.3 million from $11.1 million.
- Operating cash flow decreased to $4.4 million, while capital expenditures increased to $7.5 million.
- Mitek represented 43% of total 2022 revenue and 47% of accounts receivable at year-end, compared with 45% and 41%, respectively, in 2021.
Guidance, Outlook and Management Commentary
- The filing does not provide formal numerical revenue, earnings or cash-flow guidance.
- Management expects continued investment in research and development, clinical trials, regulatory compliance, manufacturing scale-up and U.S. commercial infrastructure.
- Cingal completed a third Phase III trial in 2022 and achieved its primary endpoint. Anika planned to engage with the FDA in the first half of 2023 regarding potential U.S. approval and was evaluating additional clinical and commercial-partnership options.
- Hyalofast enrollment reached 199 of 200 targeted patients. Management stated that the pivotal trial requires two years of follow-up and expected a potential U.S. PMA filing in 2025.
- X-Twist received 510(k) clearance and had a limited launch in 2022, with a broader launch planned for early 2023. RevoMotion began a limited launch in early 2023, with first surgeries reported in the first quarter.
- Management believes cash on hand, expected operating cash flow and available credit capacity will fund anticipated operating needs and planned investment, but future capital needs could increase with growth initiatives, acquisitions, regulatory programs or weaker-than-expected performance.
Risks, Contingencies and Unusual Items
- Internal controls: Management and Deloitte concluded that internal control over financial reporting was not effective as of December 31, 2022 because of material weaknesses involving inadequate segregation of duties, failure to identify fraud risks and deficient control activities related to a legacy corporate credit-card program. The issue involved approximately $4,000 of personal expenses by an accounting employee and immaterial personal expenses by other employees. Management stated that the financial statements were not materially misstated, but the weaknesses could have allowed material misstatements to go undetected.
- Legal contingency: Former Parcus Medical unitholders filed arbitration relating to earnout provisions. Anika could not estimate a potential loss or range of loss and intended to defend the claims.
- Customer concentration: Dependence on Mitek creates exposure to order reductions, pricing decisions, renegotiation or termination of the relationship.
- Regulatory risk: Cingal and Hyalofast remain subject to significant U.S. regulatory and clinical requirements. Delays, additional trials, adverse findings or changing FDA and international rules could affect commercialization.
- Supply chain and procedure volumes: COVID-19-related staffing, supply-chain and elective-surgery disruptions continued to affect demand, manufacturing and product adoption. Anika also relies on a limited number of suppliers, including a single contract manufacturer for certain Arthrosurface products.
- Impairment risk: Long-lived assets totaled $130.2 million. Goodwill related to the Parcus Medical and Arthrosurface reporting unit was fully impaired in 2020; remaining goodwill was $7.3 million at year-end 2022 and was not impaired in the 2022 annual assessment.
- Unusual financial items: 2022 included $3.2 million of product rationalization charges, $6.2 million of acquisition-related intangible amortization and $14.3 million of stock-based compensation.
Most Important Facts for Investors to Verify
- Whether Anika can restore positive GAAP operating income and net income while continuing to fund commercial expansion and product development.
- The sustainability of the 60% reported gross margin and the extent to which acquisition-related amortization and rationalization charges affect future results.
- Progress toward FDA discussions and potential approval of Cingal, Hyalofast and other pipeline products.
- Revenue diversification away from Mitek and the effect of the Orthovisc agreement extension on future concentration.
- Resolution and potential financial exposure from the Parcus Medical earnout arbitration.
- Remediation and auditor reassessment of the material weaknesses in internal control over financial reporting.
- Inventory demand, excess and obsolescence reserves, which totaled approximately $9.9 million at December 31, 2022 and were identified as the critical audit matter.
- Cash-burn trends, operating cash generation, capital expenditures and available borrowing capacity as investment and regulatory spending continues.